Hepatic somatostatin receptor 2 expression during premalignant stages of hepatocellular carcinoma

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 2497-2502

  Abdel Hamid, N M ^a   Mohafez, O M ^b   Zakaria, S ^c   Thabet, K ^b  

^a Kafrelsheikh University   (Egypt)

^b AL AZHAR UNIVERSITY   (Egypt)

^c DAMANHOUR UNIVERSITY   (Egypt)

Author keywords

AFP; Caspase 3; Diagnosis; GSH; Hepatocellular carcinoma; MDA; SSR2

Indexed keywords

ALPHA FETOPROTEIN; CASPASE 3; DIETHYLNITROSAMINE; GLUTATHIONE; MALONALDEHYDE; MESSENGER RNA; SOMATOSTATIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STAGING; CONTROLLED STUDY; HISTOPATHOLOGY; LIPID PEROXIDATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALPHA-FETOPROTEINS; ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; LIVER NEOPLASMS; MALE; MICE; PRECANCEROUS CONDITIONS; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84899090021     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1330-x     Document Type: Article

References (26)

1. Yu MC, Yuan JM, Govindarajan S, Ross RK. Epidemiology of hepatocellular carcinoma. Can J Gastroenterol. 2000;14(8):703-9.
2. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9(2):191-211. v.
3. Tanaka Y, Hanada K, Mizokami M, Yeo AE, Shih JW, Gojobori T, et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A. 2002;99(24):15584-9.
4. Ohata K, Hamasaki K, Toriyama K, Matsumoto K, Saeki A, Yanagi K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer. 2003;97(12):3036-43.
5. Weckbecker G, Raulf F, Stolz B, Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther. 1993;60(2):245-64.
6. Favoni RE, de Cupis A. The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach. Pharmacol Rev. 2000;52(2):179-206.
7. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30(5):781-93.
8. Reubi JC, Zimmermann A, Jonas S, Waser B, Neuhaus P, Laderach U, et al. Regulatory peptide receptors in human hepatocellular carcinomas. Gut. 1999;45(5):766-74.
9. Song SH, Leng XS, Li T, Qin ZZ, Peng JR, Zhao L, et al. Expression of subtypes of somatostatin receptors in hepatic stellate cells. World J Gastroenterol. 2004;10(11):1663-5.
10. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med. 1998;217(2):143-52.
11. Ruscica M, Arvigo M, Steffani L, Ferone D, Magni P: Somatostatin, somatostatin analogs and somatostatin receptor dynamics in the biology of cancer progression. Curr Mol Med, 13(4):555-571.
12. Naura AS, Kalla NR, Sharma RP, Sharma R. Anticarcinogenic effects of hexaamminecobalt(III) chloride in mice initiated with diethylnitrosamine. Biol Trace Elem Res. 2007;119(2):147-65.
13. Mihara M, Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem. 1978;86(1):271-8.
14. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70-7.
15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.
16. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979;76(9):4350-4.
17. Kew MC. Hepatocellular cancer. A century of progress. Clin Liver Dis. 2000;4(1):257-68.
18. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001;5(1):145-59.
19. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut. 1998;42(3):442-7.
20. Xie YM, Yan LN, Wei B, Guo MM, Tang CW. Correlation of somatostatin receptor expression in human hepatocellular carcinoma tissue to serum alpha-fetoprotein concentration]. Ai Zheng. 2007;26(7):688-92.
21. Hua YP, Yin XY, Peng BG, Li SQ, Lai JM, Liang HZ, et al. Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma. Chemotherapy. 2009;55(5):312-20.
22. Kolenko V, Uzzo RG, Bukowski R, Bander NH, Novick AC, Hsi ED, et al. Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma. Cancer Res. 1999;59(12):2838-42.
23. Sun BH, Zhang J, Wang BJ, Zhao XP, Wang YK, Yu ZQ, et al. Analysis of in vivo patterns of caspase 3 gene expression in primary hepatocellular carcinoma and its relationship to p21(WAF1) expression and hepatic apoptosis. World J Gastroenterol. 2000;6(3):356-60.
24. Reed JC. Mechanisms of apoptosis. Am J Pathol. 2000;157(5):1415-30.
25. Yadav AS, Bhatnagar D. Chemo-preventive effect of star anise in N-nitrosodiethylamine initiated and phenobarbital promoted hepato- carcinogenesis. Chem Biol Interact. 2007;169(3):207-14.
26. Sivaramakrishnan V, Shilpa PN, Praveen Kumar VR, Niranjali Devaraj S. Attenuation of N-nitrosodiethylamine-induced hepatocellular carcinogenesis by a novel flavonol-morin. Chem Biol Interact. 2008;171(1):79-88.